Recilisib sodium

产品活性：Recilisib sodium (ON 01210) 是一种辐射防护剂，可以激活细胞中 AKT 和 PI3K 的活性。

In Vitro: Recilisib sodium (up to 50 μM) shows a normal distribution of cells throughout the cell cycle, with a slight reduction in the number of cells in S-phase at 50 μM. Continuous exposure of Recilisib sodium (100 μM) does not result in cell death. Recilisib sodium treatment does not inhibit the colony forming potential of human bone marrow cells. Recilisib sodium provides dose dependent protection of human bone marrow cells at all three doses of IR. Recilisib sodium activates the phosphorylation of AKT and GSK3α/β in HFL cells. Recilisib sodium increases PI3K activity in HFL-1 cells and murine bone marrow cells in response to radiation exposure. Recilisib sodium treatment in combination with radiation alters the MAPK signaling pathway.

In Vivo: Recilisib sodium (500 mg/kg) significantly increases the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice. Recilisib sodium in combination with radiation reduces CFU numbers in mice, but the Recilisib sodium-treated mice consistently retain a capability to form differentiated colonies. Recilisib sodium treated mice have a progenitor cell population that is never completely depleted by radiation exposure.

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。